Q1 Earnings Forecast for Clene Issued By Roth Capital

Clene Inc. (NASDAQ:CLNN) – Equities researchers at Roth Capital issued their Q1 2025 EPS estimates for shares of Clene in a research note issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff forecasts that the company will earn ($0.86) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.26) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.85) EPS and Q4 2025 earnings at ($0.75) EPS.

A number of other research firms have also issued reports on CLNN. Canaccord Genuity Group reduced their price target on shares of Clene from $86.00 to $83.00 and set a “buy” rating for the company in a research report on Thursday. EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a research report on Tuesday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Clene in a research report on Thursday.

Clene Trading Down 2.7 %

NASDAQ:CLNN opened at $4.69 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.99 and a current ratio of 0.99. Clene has a twelve month low of $3.82 and a twelve month high of $12.00. The company has a 50-day moving average of $5.46 and a 200-day moving average of $6.05.

Insider Activity at Clene

In other Clene news, Director David J. Matlin acquired 92,307 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $438,458.25. Following the transaction, the director now owns 444,491 shares of the company’s stock, valued at $2,111,332.25. This trade represents a 26.21 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Mortenson bought 20,512 shares of the business’s stock in a transaction on Monday, September 30th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $97,432.00. Following the purchase, the insider now directly owns 28,949 shares in the company, valued at approximately $137,507.75. This represents a 243.12 % increase in their position. The disclosure for this purchase can be found here. 25.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC bought a new position in shares of Clene Inc. (NASDAQ:CLNN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned approximately 0.19% of Clene as of its most recent filing with the SEC. 23.28% of the stock is owned by institutional investors and hedge funds.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.